Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Journal Article


Authors: Karantanos, T.; Politikos, I.; Boussiotis, V. A.
Article Title: Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies
Abstract: Hodgkin's lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemotherapy followed by autologous stem cell transplantation (ASCT), which remains the standard of care with curative potential for refractory or relapsed HL. Nevertheless, a significant percentage of such patients will progress after ASCT, and allogeneic hematopoietic stem cell transplantation remains the only curative approach in that setting. Recent advances in the pathophysiology of refractory or relapsed HL have provided the rationale for the development of novel targeted therapies with potent anti-HL activity and favorable toxicity profile, in contrast to cytotoxic chemotherapy. Brentuximab vedotin and programmed cell death-1-based immunotherapy have proven efficacy in the management of refractory or relapsed HL, whereas several other agents have shown promise in early clinical trials. Several of these agents are being incorporated with transplantation strategies in order to improve the outcomes of refractory or relapsed HL. In this review we summarize the current knowledge regarding the mechanisms responsible for the development of refractory/relapsed HL and the outcomes with current treatment strategies, with an emphasis on targeted therapies and hematopoietic stem cell transplantation.
Keywords: pathophysiology; hematopoietic stem cell transplantation; immunotherapy; reed-sternberg cells; phase-ii trial; nf-kappa-b; regulatory t-cells; progression-free survival; bone-marrow; epstein-barr-virus; complete remission; high-dose chemotherapy; autologous; 1st; novel agents; stem-cell-transplantation; relapsed/refractory hodgkin's lymphoma
Journal Title: Blood and Lymphatic Cancer: Targets and Therapy
Volume: 7
ISSN: 1179-9889
Publisher: Dove Medical Press Ltd  
Date Published: 2017-05-09
Start Page: 37
End Page: 52
Language: English
ACCESSION: WOS:000402379000001
DOI: 10.2147/blctt.s105458
PROVIDER: wos
PMCID: PMC5502320
PUBMED: 28701859
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ioannis   Politikos
    107 Politikos